Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$16.85 USD
+0.69 (4.27%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.84 -0.01 (-0.06%) 4:42 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
RNAC 16.85 +0.69(4.27%)
Will RNAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RNAC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RNAC
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
RNAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
Other News for RNAC
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis